You did everything right. You found a prescriber, you titrated up, you got through the first three months of nausea. And now the thing standing between you and your next dose isn't your body — it's a form.

Maybe the prior authorization is still pending. Maybe your plan reclassified the drug. Maybe you just found out that the program you were counting on doesn't cover your particular situation. Whatever the reason, the pharmacy is telling you no, and nobody is telling you what to do with the four, six, or ten weeks in between.

Here's the part that almost never gets explained: an access gap isn't a pause button. Your body doesn't freeze where you left it and wait. What happens in those weeks — and specifically what happens to your muscle — depends almost entirely on what you do with them.

The strange thing about 2026 is that GLP-1s became dramatically more affordable and dramatically more interrupted at the same time.

The Medicare GLP-1 Bridge, which launched July 1, brought a flat $50 monthly copay for Wegovy, the Zepbound KwikPen, and Foundayo to eligible Part D enrollees — the first time Medicare has covered these medications for weight management at all. An estimated 3.8 million beneficiaries could qualify. But the Bridge runs outside the normal Part D pathway, through a single central processor, and that architecture creates friction at exactly the points where prescriptions get abandoned.

1. Eligibility is narrower than it sounds

There are three tiers, and two of them are narrow: a BMI of 35 or more on its own; a BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; or a BMI of 27 or more with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. One detail worth knowing if you've already lost weight: BMI is assessed as of when you started GLP-1 therapy, not today.

2. The paperwork sits with an already-stretched prescriber

Physicians have been vocal since launch that the administrative workload of Bridge prescribing can rival the clinical work itself. Every step — documentation, prior authorization, an unfamiliar claims pathway — is a place where a prescription can sit for weeks. Nobody calls to tell you it's sitting.

3. The $50 doesn't behave like other copays

The Part D deductible doesn't apply, and no part of the $50 counts toward your annual out-of-pocket threshold. There's no low-income subsidy under the Bridge, so Extra Help can't cushion it either. On a fixed income, $50 every month — uncushioned, indefinitely — is itself the barrier.

4. It's prescribed for weight management only

If you're prescribed the same drug for type 2 diabetes or sleep apnea, you stay in your regular Part D plan and pay your plan's cost-sharing, even when that's far more than $50. Women who assumed one program covered them can discover mid-refill that they were in a different lane the whole time. And the Bridge itself is a demonstration scheduled to end December 31, 2027 — planning your body composition around a program with a sunset clause is a different exercise than planning around a permanent benefit.

None of that is a reason to skip the program — $50 a month is transformative if you qualify. It's a reason to build a plan that survives the gap.

Appetite comes back before the weight does. As the medication clears, appetite suppression fades and hunger signalling returns — often more insistently than before, because your body has been in a deficit and is defending its fat stores. That's physiology, not a failure of willpower. Our post on what happens when you stop Ozempic or Wegovy walks through that timeline week by week.

Then the weight returns. In the STEP 1 extension, participants who had lost an average of 17.3% of their body weight over 68 weeks regained about two-thirds of it within a year of stopping, with blood pressure, cholesterol, and blood sugar drifting back toward baseline.

And here's the part that matters for muscle — and the part the research hasn't closed. Fat is restored faster and more efficiently than skeletal muscle, particularly without a training stimulus, so clinicians expect regain to return disproportionately as fat, leaving you at a similar number on the scale with less muscle and more fat than when you started. A 2026 systematic review was blunt about the caveat: no study has yet directly measured body composition after people stop. What's established is the asymmetry of the biology, not a measured number. It's real enough to plan around — and the plan is the same either way.

That asymmetry is the whole reason an access gap deserves a plan. The scale isn't the thing at risk. Your body composition is — which is exactly what measuring fat versus muscle is for.

Women carry less muscle to begin with, and lean mass already declines with age — faster through perimenopause and after. A cycle that quietly trades muscle for fat lands on a smaller starting reserve. And muscle is metabolically active tissue: less of it means lower resting energy expenditure, which makes the next round of weight loss harder than the last one, whether that round happens on medication or off it.

The good news, and it's real: muscle isn't automatically forfeit. In a 2026 study of patients on semaglutide 2.4 mg, lean mass dipped early and then stabilised, grip strength improved over twelve months, and the share of participants meeting criteria for sarcopenic obesity fell from 49% to 33%. Body composition responds to what you feed it and how you load it — not only to whether the drug is in your system.

The single most counterproductive move is the one most women make in week one: eating dramatically less to "hold the line" without the medication. A steep, unsupported deficit combined with returning hunger and no resistance training is the exact recipe for losing lean mass — and it usually collapses into rebound eating within a month.

Practical tip: during a gap, protein becomes more important, not less. On the drug, low protein was a consequence of low appetite. Off it, you have appetite back — which means for the first time in months, hitting 80–130g a day is actually easy. Use the window.

Resistance training is the other half, and it doesn't need to be impressive. Two sessions a week of compound movements is enough to signal that the muscle is in use and shouldn't be broken down for fuel. Our beginner protocol works exactly as well off the medication as on it.

Muscle protection buys you time. Closing the gap is still the goal — and most gaps close faster with pressure applied in the right place.

Everything above still applies, with one addition: a planned taper is far more protective than an abrupt stop, and the protein-and-resistance foundation needs to be in place before the last dose, not after. Before you stop, it's worth being honest about what's already built.

A protein habit that will hold when you're hungry again
Regular resistance training — enough to have built real muscle
A plan for the weeks the medication is clearing, not just the day you stop
Someone tracking the right things with you, so early regain gets caught early

Coverage rules change constantly, and none of this is a substitute for your own prescriber. What doesn't change is the part you control: what you eat and how you load your muscles while you wait.